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Aim: Hepatocellular carcinoma (HCC) is increasing world-
wide, and is frequently attributed to rising rates of hepatitis C
virus infection and interactions between viral and environmen-
tal risk factors. Because of Egypt’s unique risk factor profile, we
analyzed data from the Gharbiah Population-Based Cancer
Registry for the period 1999–2003 to characterize demo-
graphic and geographic patterns of cases in this province.
Methods: We calculated age- and sex-specific and age- and
sex-standardized HCC incidence rates for the eight districts in
Gharbiah. We also compared rates from Gharbiah with the
USA (US Surveillance Epidemiology and End Results [SEER]
database).
Results: The analysis revealed a higher incidence in males
than in females, significant geographic variations among
districts, and a higher incidence in Gharbiah than that
reported by SEER.
Conclusion: The findings of this study document the hetero-
geneous distribution of HCC at regional and international
levels. This population-based registry offers the opportunity
for careful representative studies of various etiologies, par-
ticularly infectious and/or environmental factors that may
contribute to risk.
Key words: age-specific rates, developing countries,
geographic variation, liver cancer, USA
INTRODUCTION
LIVER CANCER RAPIDLY reduces quality of life andtypically causes death 6 months-1 year from diag-
nosis.1 Globally, it is the fifth leading cause of cancer
and the third leading cause of cancer death.1,2 This
cancer varies widely in incidence throughout the world,
with rising incidence in Egypt. The primary risk factors
for hepatocellular carcinoma (HCC) are hepatitis B virus
(HBV), hepatitis C virus (HCV), dietary aflatoxin expo-
sure, and chronic alcohol consumption.1,2
Prior to the introduction of the HBV vaccine, chronic
infection with HBV was generally high, with developing
countries sharing the greatest burden.3 Consequently,
HBV was the dominant etiologic factor in the develop-
ment of HCC. This is largely still true in Egypt, because
vaccination programs were not started until the 1980s.
More recently, HCV has begun to eclipse HBV in inci-
dence in many countries throughout North America,
Europe, and the Middle East.4,5 The rates of HCV in Egypt
are among the highest in the world, with a prevalence rate
of up to 20%.6,7 Although a HBV vaccine program has
been successfully implemented, with childhood cover-
age estimated at 95%-100%, most people born 20 years
ago or earlier in Egypt have not been vaccinated.8,9
Hospital-based studies from Egypt have reported an
overall increase in the relative frequency of all liver-
related cancers in Egypt (>95% as HCC), from ap-
proximately 4% in 1993 to 7.3% in 2003.10 Recent
investigations in Egypt have shown the increasing
importance of HCV infection in the etiology of liver
cancer, estimated to account for 40–50% of cases, and
the declining influence of HBV and HBV/HCV infection
(25% and 15%, respectively).10–12
Few studies in Egypt have fully measured the presence
of aflatoxins and their impact on liver disease there. A
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recent study by el-Zayadi et al.13 examined 200 HCC
cases and 120 healthy controls and detected aflatoxin
B(1) in 17% of the HCC cases compared to 9.4% of the
healthy controls (risk ratio = 2). In 2005, Sayed et al.14
performed a cross-sectional analysis on risk factors for
liver disease in a rural population south of Cairo to
evaluate aflatoxin exposure in serum. They found afla-
toxin B(1) to be associated with hepatitis B surface
antigen seropositive patients (odds ratio = 6.2) and anti-
HCV seropositive patients (odds ratio = 2.5).
In addition to HBV, HCV, and aflatoxins, other risk
factors have been linked to HCC, including chronic
alcohol consumption and hemochromatosis. Although
alcohol plays a significant role in the etiology of HCC in
many countries, it was not examined in this study
because the prevalence of alcohol consumption in
Egypt is extremely low.15,16 Hemochromatosis also was
not investigated in this study, because in Egypt it is
extremely rare.17,18
With assistance and quality assurance from the US
National Cancer Institute (NCI),19 Egypt successfully
created a population-based cancer registry in Gharbiah
province (Fig. 1) that has been successfully functional
since 1999. The first year of the registry data (1999)
showed that the age-standardized annual incidence rate
of HCC was ~20.6/100 000 in males and ~5.2/100 000
in females. A comparison of data from the Gharbiah
Population-based Cancer Registry (GPCR) for the
period 1999–2001 with other countries in the Middle
East Cancer Consortium showed that the liver cancer
incidence rate was seven times greater than the next
highest country rate, and more than three times the rate
reported by the US Surveillance Epidemiology and End
Results (SEER).19 Our study was designed to characterize
the demographic and geographic patterns of HCC cases
in this region to lay the groundwork for future research
directed at understanding the complex etiology of this
disease. Accordingly, we retrieved and analyzed data of
all HCC patients included in the GPCR from January 1
1999 to December 31 2003. We analyzed the demo-
graphic and geographic characteristics of HCC patients
and compared patterns with those of HCC cases in the
US SEER registry for this period.
METHODS
Characteristics of the study region
GHARBIAH PROVINCE IS located in the middle ofthe Nile Delta, approximately 100 km north of
Cairo. The province population (4.2 million people,
5.7% of Egypt) has a density of ~1752/km2, making it
the tenth most densely populated province in Egypt
(Egypt has a total of 27 provinces). The male : female
ratio in the Gharbiah Province is 1.02:1, and the age
structure resembles that of the rest of the country, with
47% of the population <20 years and 3.6% >65 years.20
Gharbiah Province is considered an urban–rural prov-
ince by the Central Agency for Public Mobilization and
Statistics with 31% of the population in urban areas and
69% in rural areas.20 Each of its eight districts has its
own main city. The capital of Gharbiah Province is the
city of Tanta, which serves as the headquarters for the













C - El Mehalla
D - Samanoud
E - Kafr El Zayat
F - Tanta
G - El Santa
H - Zefta
Figure 1 Northern Egypt (Nile Delta), Gharbiah Province, and its eight districts. (Map: http://www.meccegypt.org).
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of 316 villages and is mainly agricultural, but one dis-
trict (El Mehalla) is a major textile producer in Egypt.
The annual incidence rates of HCC were based on popu-
lation data estimated using linear interpolation between
pairs of published government census population infor-
mation. This preliminary study used an annual linear
interpolation from the 1996 census data and the 2001
and 2005 population projections.20
GPCR data
The GPCR was established in 1998 as part of the Middle
East Cancer Consortium (MECC) Joint Cancer Registra-
tion Project,21 and it is affiliated with the Egyptian
Ministry of Health and Population. The registry actively
seeks all cases in Gharbiah Province, regardless of
inpatient/outpatient status or whether patients were
seen in public or private hospitals. Information is gath-
ered from medical records of government and private
hospitals and clinics, death certificates, and histopathol-
ogy laboratories and radiology clinics. A team of regis-
trars trained by the International Agency for Research on
Cancer (IARC) and Emory University School of Public
Health in Atlanta, USA, conduct regular visits with each
collaborating center to obtain the data and review its
quality using the standard review process of the IARC.
Data quality was assessed in 2002 for completeness of
coverage and reliability of registration. In addition to
computer checks through CanReg software; external
auditing was done by Emory University staff in 2002.
Coverage was found to exceed 90% of the Gharbiah
population.22
The registry conducts routine data cleaning by stan-
dardizing field entries and removing duplicate entries.
Inconsistencies were addressed by reviewing medical
records. We obtained the data of all liver cancer cases
diagnosed and included in the registry from January 1
1999 to December 31 2003 (n = 1309). Our case defi-
nition was restricted to those with an International Clas-
sification of Diseases (ICD)-10 topology code of 22.0
and HCC morphology. Cases were excluded if they did
not satisfy both elements of the case definition or if they
had missing values, and if inconsistencies were not
resolved after examining medical records. This process
reduced the total number of cases to 1186 (removing
123 cases). The following variables were obtained for
each case: registry patient number, sequence number,
age at diagnosis, date of birth, sex, usual residential
address, date of diagnosis, basis of diagnosis, primary
site code (ICD-0–3), morphology codes, histology
type, behavior, grade/differentiation/cell indicator,
and summary stage at diagnosis. Additional variables
included family history, marital status, smoking history,
religion, occupation, and treatment data. Unfortunately,
hepatitis data are not currently included in the manage-
ment protocol for HCC cases at the GPCR. Thus, patient
HBV and HCV status were unavailable for this study.
Additionally, because this study was retrospective and
the cases in our sample were all deceased, there was no
way to independently acquire HBV/HCV data.
Statistical analyses
The annual and average age- and sex-specific incidence
rates for the period 1999–2003 were calculated using
the number of HCC cases as the numerator and age–
sex-specific population data from Egypt as the deno-
minator. Univariate analyses were used to develop a
descriptive profile for the cases using demographic indi-
cators and information regarding the geographic loca-
tion of residence at the time of diagnosis for each case.
Interannual variation in the number of cases during the
5-year period in Gharbiah and in individual districts
was examined using c2-test analyses. Rate ratios (RR)
were calculated to examine the differences among the
eight districts of Gharbiah. We also calculated and com-
pared the incidence rates for HCC among the cases
residing in urban and rural regions of Gharbiah.
We also compared the HCC incidence rates for the
years 1999–2003 in Gharbiah to those for 1999–2002
from the US SEER.23 The age-specific incidence rates for
Gharbiah and the USA were adjusted to the world mil-
lion,24 and the age-adjusted rates of the two regions were
compared. The RR estimates and 95% confidence inter-
vals (CI) were used to estimate an age-specific incidence
variation between Gharbiah and the USA. All statistical
operations were conducted using SAS software, version
9.1 (SAS Institute, Cary, NC, USA).
Ethical oversight
Our study protocol was approved by the Internal Review
Board at the University of Michigan and the registry
ethical committee in Egypt.
RESULTS
Incidence and descriptive features of HCC
THE NUMBER OF HCC cases registered in theGPCR from 1999 through 2003 was fairly stable
over the 5-year study period, with 200–250 cases per
year (Table 1). Cytohistopathological confirmation
of the primary tumor was the basis of diagnosis in
33.5% of cases. Non-microscopic (laboratory marker/
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radiological) diagnosis was the basis of diagnosis in
43.2% of cases. Approximately 23% of cases were diag-
nosed by death certificate only. The majority of cases
(96.5%) were aged 40 years and older. Of the 1186
HCC cases, 949 (80%) were males and 237 (20%) were
females. Males had consistently higher incidence rates
than females for all age groups above 40 years (Table 2).
Geographic patterns in incidence
among districts
Geographically, 1062 cases (89.5%) were reported
being born in Gharbiah, supporting the notion that
the population in this region is fairly stable and
suggesting that relevant exposures largely occurred in
Gharbiah. The eight districts varied considerably in
population, representing the following percentages
of the total provincial population: Tanta 23.9%, El
Mehalla 22.6%, Kafr El Zayat 8.7%, Zefta 9.7%, El
Santa 9.2%, Samanoud 7.4%, Kotour 7.2%, Basyoon
6.3%.20 In addition to being the most densely popu-
lated districts, Tanta and El Mehalla jointly account for
approximately 56.4% of the cases in the registry. The
remaining six districts, however, did not all contribute
cases in relative proportion to their population densi-
ties. The interannual variation in the number of cases
during the 5-year period in Gharbiah and in individual
districts was examined using c2-test analyses. No
significant differences were found, except in Zefta
(P = 0.01; data not shown), which had more cases
diagnosed in 2000 than in any other year.
A similar proportion of cases came from rural and
urban regions of the governorate, accounting for 50.7%
and 49.3%, respectively. However, the mean age-
adjusted incidence rates were greater for the cases resid-
ing in urban (15.8/100 000 person/year [PY]) than in
rural (8.6/100 000 PY) areas. Urban residents had an
incidence rate 1.84 times greater than that among rural
residents (95% CI 1.42, 3.13).
The mean age-adjusted incidence rates for HCC
in Gharbiah and its eight districts for males, females,
and the total population (1999–2003) also varied
(Table 3; Fig. 2). The c2-test analysis of the HCC
incidence rates of the eights districts showed statisti-
cally significant variations (P < 0.0001), largely the
result of variations among males (P < 0.0001). Overall,
Kotour had the highest incidence rates among males
and the total population (24.1/100 000 PY and 12.9/
100 000 PY, respectively), with Samanoud having the
lowest rates (10.3/100 000 PY and 6.1/100 000 PY,
respectively). The incidence rates among females
showed a different distribution, with the highest occur-
ring in Tanta and El Mehalla (5.8/100 000 PY) and the
lowest in Zefta (1.5/100 000 PY). Statistically signifi-
cant differences were not observed among females,
most likely as a result of the small sample size and
insufficient power.
The RR for the HCC incidence rates among the eight
districts varied considerably (Table 4). Among the
largest RR were those of Kotour compared with Saman-
oud (2.34 times greater) and Kotour compared with
Zefta (1.94 times greater). People in Tanta had 1.94
times the rate of HCC as those in Samanoud. Other
significant RR varied between 1.29 and 1.85.
Table 1 Characteristics of people diagnosed with hepatocellu-







Sex Male 949 80.0
Female 237 20.0






Religion Muslim 1162 98.0
Christian 24 2.0
Governorate of birth† Gharbiah 1062 89.5
Other 123 10.5
Region of residence Tanta 362 30.5
El Mehalla 307 25.9
Kafr El Zayat 113 9.5
Kotour 105 8.9




Urban/rural distribution Urban 585 49.3
Rural 601 50.7










†n = 1185; missing birth place information for one patient.
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Comparisons between incidence rates in
Gharbiah versus the USA
Our results showed that the overall age-adjusted HCC
incidence rate in Gharbiah (10.6/100 000) is signifi-
cantly higher than the rate observed in the USA (3.0/
100 000), with a rate ratio of 3.53 (95% CI 3.11, 4.67).
The incidence rates among males were significantly
higher than those among females in both Egypt and the
USA. Males in Egypt had incidence rates 4.3 times higher
than females (95% CI 3.11, 5.66), and males in the USA
had rates 3.3 times higher than females (95% CI 3.16,
4.34). In addition, age-specific incidence rates were sig-
nificantly higher in Egypt compared to the USA for all age
groups older than 40 years (Table 5). Significant differ-
ences in the rates among the younger age groups were not
apparent. These age patterns remained consistent when
examining males and females separately.
DISCUSSION
ANALYSES FROM THIS population-based cancer reg-istry were based on HCC cases that appear to be
largely complete and highly representative. Case data














0–24 0.6 0.4 0.4 0.3 1.42 (0.03, 56.1)
25–29 0.6 0.5 0.2 0.1 3.30 (0.02, 161.0)
30–34 1.0 0.8 1.4 1.1 0.73 (0.1, 13.8)
35–39 2.2 1.8 1.6 1.3 1.42 (0.2, 9.1)
40–44 10.0 9.4 2.2 2.1 4.40 (1.0, 8.7)
45–49 19.4 21.0 4.0 4.8 4.37 (1.5, 7.3)
50–54 30.4 48.1 7.2 11.3 4.24 (1.9, 6.5)
55–59 35.8 73.8 8.8 19.2 3.85 (1.8, 5.9)
60–64 36.0 86.0 6.4 13.9 6.19 (2.7, 8.5)
65–69 23.2 75.6 6.0 19.7 3.84 (1.6, 6.3)
70–74 19.4 101.5 6.8 31.5 3.22 (1.3, 5.6)
75+ 14.8 105.2 2.2 13.6 7.76 (1.9, 11.9)
CI, confidence intervals; IR, incidence rate; PY, person/year; RR, rate ratios.
Table 3 Mean age-adjusted incidence rates per million for
hepatocellular carcinoma in Gharbiah, Egypt and its districts











Gharbiah (all) 16.7 4.0 10.6
Kotour 24.1 3.3 12.9
Tanta 19.9 5.8 12.3
El Mehalla 18.4 5.8 12.1
Kafr El Zayat 19.0 3.7 11.1
Basyoon 17.9 3.2 10.4
El Santa 15.4 2.6 8.8
Zefta 12.5 1.5 6.9

















C - El Mehalla
D - Samanoud
E - Kafr El Zayat
F - Tanta
G - El Santa
H - Zefta
Figure 2 Mean age-adjusted incidence rates for hepatocellular
carcinoma in the eight districts of Gharbiah (1999–2003),
standardized to the world million (Parkin et al. 1997). (Map:
http://www.meccegypt.org).
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from the GPCR were obtained from virtually all sources
in the province, and there is no reason why agencies
from various sectors would not have participated in the
registry. GPCR is financially and scientifically supported
by the US National Cancer Institute, and has quality
assurance from SEER and the International Association
of Cancer Registries. Standard procedures for training
registrars and for data collection, processing, and trans-
mission enhanced the accuracy of data. In addition, the
population-based structure improves our ability to draw
conclusions about the entire province from the study
results. For these reasons, our study is unlike other
hospital- or clinic-based reports that have previously
appeared for HCC in Egypt, as it includes essentially all
cases in the study area. Thus, the results represent a high
degree of internal and external validity. Furthermore,
data on the vast majority of cases included complete
demographic and geographic information. It is reassur-
ing that the number of HCC cases reported per year did
not vary during the 5 years of this study. Therefore, the
case data that we analyzed should be considered valid
for the populations at risk and the results generalizable,
at least to the people of Gharbiah Province.
At first glance, the approximately 23% of cases
diagnosed using only the death certificate might seem
overly high. This percentage, however, is not unusually
high for liver cancer.1 Due to the difficulty in diagnos-
ing HCC, even in developed countries, many cases are
not diagnosed until death.1,25 This is more a limitation
of current technology than specific registry methods. In
fact, the overall proportion of cancers diagnosed by
death certificate only in the Gharbiah registry is only
6–7%. It is also unlikely that missed cases would sig-
nificantly alter our findings. The GPCR has a reported
coverage rate of greater than 90% for Gharbiah Prov-
ince.22 The number of cases could be underestimated
due to HCC being misclassified as cirrhosis, but there
is no reason to believe that this underestimation is
biased in any way. Access to health care is similar
across the province, and there is nothing to suggest
Table 4 Mean incidence rate ratios (RR) for hepatocellular carcinoma among Gharbiah districts per 100 000 PY, 1999–2003
RR = R↓/C→ Kotour Tanta El Mehalla Kafr El Zayat Basyoon El Santa Zefta Samanoud






























RR: row district : column district. 95% confidence limits are given in parentheses. NS, not significant; PY, person/year.
Table 5 Age-specific Egyptian hepatocellular carcinoma inci-
dence rates for 1999–2003 compared to US Surveillance Epi-
demiology and End Results (SEER) data (1999–2002). Rates













0–24† – – – –
25–29 0.3 0.3 1.10 0.12, 10.21
30–34 1.0 0.5 2.09 0.57, 7.66
35–39 1.6 0.6 2.47 0.89, 6.87
40–44 6.1 1.8 3.37 1.90, 5.96
45–49 13.9 5.2 2.70 1.79, 4.06
50–54 31.2 7.3 4.28 3.10, 5.93
55–59 49.7 8.9 5.58 4.14, 7.53
60–64 51.1 11.9 4.28 3.10, 5.93
65–69 50.1 16.5 3.05 2.11, 4.39
70–74 67.8 19.6 3.46 2.35, 5.08
75+ 39.1 18.3 2.14 1.19, 3.85
Total 10.6 3.0 3.53 3.11, 4.02
†Complete SEER data unavailable. CI, confidence intervals;
IR, incidence rate; PY, person/year; RR, rate ratios.
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that physicians diagnose differently in any systematic
way.
This study presents various findings that are similar
to, but also different from, those that have previously
addressed HCC in the Middle Eastern region. As has
been shown consistently in other studies, male inci-
dence was considerably greater than that for females.
Worldwide, estimates show males to be 1.3–3.6 times as
likely to develop HCC as females.1 In high-risk coun-
tries, sex ratios tend to be higher, and this is demon-
strated here by the lower rate ratio seen in the USA
versus Egypt. A satisfactory biologic interpretation has
yet to be demonstrated. Several hypotheses have been
investigated, including the interaction of sex hormones
with HBV, leading to a different natural history depend-
ing on the sex of the individual or the impact of sex-
specific exposure.26,27
Interestingly, the incidence rate of HCC in Gharbiah
was 3.5 times higher than that reported in the USA. Such
results were seen in the overall age-adjusted incidence
rates, as well as the age-specific rates in age groups older
than 40 years, among both males and females. This
finding expands upon reports in the US NCI and MECC
publications for a shorter period, 1999–2001.19 Our
similar findings for a longer period suggest that variation
in rates truly reflect different risk factor profiles of these
two populations, warranting further prospective studies.
The most notable finding of this study, however, was
the statistically significant geographic variation in inci-
dence of HCC among districts within Gharbiah Province.
The incidence ranged from 12.9/100 000 PY (Kotour) to
less than half that rate at 6.1/100 000 PY (Samanoud).
Districts were similar with respect to age distribution and
sex ratios, suggesting that the at-risk populations were
fairly homogeneous. Consequently, this observed het-
erogeneity was likely attributable to variations in local
risk factors that future studies may investigate.
Another interesting finding demonstrated that HCC
incidence among urban individuals was nearly twice
that of rural residents. Several studies have postulated
that the HCV epidemic in Egypt has disproportionately
affected rural populations, which should be reflected in
the distribution of HCC cases.28,29 The HCV epidemic in
Egypt is unique. Egypt developed the world’s highest
rates of HCV infection over a short period of time,
largely due to a massive public health campaign. The
vast majority of infections among individuals aged
30 years and older can be explained by parenteral
anti-Schistosomal therapy (PAT) and other iatroge-
nic exposures.29–32 The anti-Schistosomiasis campaign
extended from the 1950’s to the 1980’s, with peak
transmission probably occurring during the 1960s and
1970s. In 1982, praziquantal, an oral treatment for
Schistosomiasis, was introduced, and the use of PAT
declined. Since Schistosomiasis was a greater problem in
rural regions, these populations were more affected by
the PAT campaign, and consequently, HCV transmis-
sion.30,32 With iatrogenic infections nearly eliminated,
person-to-person transmission is presently the domi-
nant route, which should preserve the urban/rural dis-
parity. Higher rates of HCV infection should manifest as
higher rates of HCC.
The higher HCC incidence among urban residents
could represent better access to medical facilities, result-
ing in an underestimate of HCC in rural populations. It
is also possible that the peak of the cohort with PAT-
related HCV transmission has not yet matured, suggest-
ing the incidence of HCC due to HCV is still increasing
and competing with HBV-related HCC incidence. This
could mean a shift in the burden from urban to rural
regions is currently underway and will be discernible in
the near future. It should also be noted that disease
progression from HCV to HCC may take up to 20 years
and the incidence of HCC can increase in both urban
and rural area in Egypt over the next few years. The risk
factors of most importance in this region include HBV,
HCV, and dietary aflatoxins. Unfortunately, we were
unable to acquire data on the HBV and HCV status of
our cases, as testing is not standard protocol for patient
intake and management at the GPCR. Due to the retro-
spective nature of our study, we were unable to inde-
pendently test cases, as they were all deceased at the
time of study initiation. Nevertheless, several studies in
Egypt have documented the general prevalence of HCV
and HBV throughout the country, and we can use these
results to help guide our inference.
Several small-scale hospital-based studies have been
conducted to examine the etiologic significance of the
primary HCC risk factors in Egypt, although it should be
noted that they have not assessed geographic variation.
These studies have shown the increasing importance of
HCV in liver cancer, estimated to account for 40–50% of
liver cancer cases, and the declining influence of HBV and
HBV/HCV infection, 25% and 15%, respectively.10–12
These studies also have documented an overall increase
in the relative frequency of liver cancer in Egypt from
approximately 4.0% in 1993 to 7.3% in 2003.10 Such
increases in liver cancer are generally attributed to HCV.
Since chronic HCV does not typically lead to carcino-
genesis for 10–30 years following infection, the rates of
liver cancer can be expected to continue increasing until
the cohort of PAT-related infected individuals has
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worked its way through.10,29 This suggests that the true
burden of liver cancer in Egypt has yet to be realized.
Data on schistosomiasis infection in these cases were
unavailable. While the role of hepatic schistosomiasis
has long been controversial, the prevailing view today is
that it has limited influence in the etiology of HCC in
Egypt. Epidemiological studies of HCC clearly identified
HBV, HCV, or HBV/HCV coinfection as important, but
schistosomiasis could not be identified as a statistically
significant independent risk factor.19,33 For these reasons,
we do not feel that the lack of schistosomiasis infection
data influences our conclusions.
As in many developing countries, Egypt is undergoing
an epidemiologic transition. With increasing urbaniza-
tion, smoking rates, environmental exposures, and
aging, in addition to the maturing HCV epidemic, it is
likely that HCC will continue to rise in the next few
decades. Therefore, further studies to assess the magni-
tude and risk factors of HCC in Egypt and other devel-
oping countries seem warranted. Our study produced
important preliminary insights that can be used to
develop more refined, prospective analyses of HCC risk
in Egypt. Ongoing collaborations are building upon
these preliminary findings to develop studies that will
examine cases from the point of intake and acquire
HBV/HCV test results to expand our inference regarding
the relative importance of certain risk factors on HCC in
Egypt. Such analyses should help define the complex
etiology of HCC, enabling policy makers to create tar-
geted and more efficient prevention programs.
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